81 related articles for article (PubMed ID: 20837369)
1. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
Herz M; Gaspari F; Perico N; Viberti G; Urbanowska T; Rabbia M; Wieczorek Kirk D
Int J Cardiol; 2011 Sep; 151(2):136-42. PubMed ID: 20837369
[TBL] [Abstract][Full Text] [Related]
2. No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Sturm S; Bentley D; Jordan P; Russell-Yarde F; Ruf T
J Cardiovasc Pharmacol; 2012 Mar; 59(3):288-97. PubMed ID: 22113345
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
Sanwald-Ducray P; Liogier D'ardhuy X; Jamois C; Banken L
Clin Pharmacol Ther; 2010 Aug; 88(2):197-203. PubMed ID: 20336066
[TBL] [Abstract][Full Text] [Related]
4. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
[TBL] [Abstract][Full Text] [Related]
5. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Lincoff AM; Tardif JC; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
Am Heart J; 2013 Sep; 166(3):429-34. PubMed ID: 24016490
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
8. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
[TBL] [Abstract][Full Text] [Related]
9. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
10. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Lecka-Czernik B
IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Han CL; Qu CZ
J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
[TBL] [Abstract][Full Text] [Related]
12. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
[TBL] [Abstract][Full Text] [Related]
13. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
[TBL] [Abstract][Full Text] [Related]
14. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
Morici N; Savonitto S; Ponticelli C; Schrieks IC; Nozza A; Cosentino F; Stähli BE; Perrone Filardi P; Schwartz GG; Mellbin L; Lincoff AM; Tardif JC; Grobbee DE
Am J Med; 2017 Sep; 130(9):1068-1075. PubMed ID: 28344139
[TBL] [Abstract][Full Text] [Related]
15. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
[TBL] [Abstract][Full Text] [Related]
17. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
[TBL] [Abstract][Full Text] [Related]
18. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
[TBL] [Abstract][Full Text] [Related]
19. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients.
So WY; Kong AP; Ma RC; Ozaki R; Szeto CC; Chan NN; Ng V; Ho CS; Lam CW; Chow CC; Cockram CS; Chan JC; Tong PC
Diabetes Care; 2006 Sep; 29(9):2046-52. PubMed ID: 16936151
[TBL] [Abstract][Full Text] [Related]
20. Modification of Diet in Renal Disease equation in the risk stratification of contrast induced acute kidney injury in hospital inpatients.
Erselcan T; Hasbek Z; Tandogan I; Gumus C; Akkurt I
Nefrologia; 2009; 29(5):397-403. PubMed ID: 19820751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]